Business Context and Reporting Period
Company: Alcon, Inc.
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: Three and six months ended June 30, 2003 (filed August 6, 2003)
Business Overview: Alcon is a global ophthalmic company operating through two segments: Alcon United States and Alcon International. The company markets pharmaceuticals, surgical equipment/devices, and consumer eye care products.
Key Financial Metrics
(In millions, except per share data)
| Metric | 3 Months Ended June 30, 2003 |
6 Months Ended June 30, 2003 |
|---|---|---|
| Sales (Revenue) | $925.4 | $1,732.5 |
| Gross Profit | $658.3 | $1,212.1 |
| Gross Margin | 71.1% | 70.0% |
| Operating Income | $260.9 | $455.3 |
| Net Earnings | $178.2 | $308.4 |
| Diluted EPS | $0.57 | $1.00 |
| Cash from Operations | N/A | $427.4 |
| Cash & Equivalents (End of Period) | $806.6 | $806.6 |
| Short-Term Borrowings | $1,429.9 | $1,429.9 |
| Long-Term Debt | $72.8 | $72.8 |
Material Changes vs. Prior Period
- Revenue Growth: Global sales increased 14.3% year-over-year for both the three-month and six-month periods. Organic growth (excluding currency) was 10.1% for the quarter and 10.3% for the six months.
- Profitability: Net earnings rose 9.5% for the quarter and 20.1% for the six months compared to 2002. Operating income increased 10.1% for the quarter and 17.2% for the six months.
- Segment Performance:
- Pharmaceuticals: Led growth with a 25.4% increase in Q2 sales, driven by glaucoma (Travatan), allergy (Patanol/Opatanol), and infection products (Vigamox).
- Surgical: Sales grew 8.2% in Q2, driven by cataract and vitrectomy products. Refractive sales declined 1.5% due to economic conditions.
- Consumer Eye Care: Sales grew 4.7% in Q2.
- Expense Trends: Selling, general, and administrative (SG&A) expenses increased as a percentage of sales (31.5% vs. 30.5% in Q2 2002) due to new product launches and sales force expansion. R&D expenses also increased slightly as a percentage of sales.
- Liquidity: Cash and cash equivalents decreased by $161.3 million in the first half of 2003, primarily due to the repayment of short-term borrowings and dividend payments.
Guidance, Outlook, and Risks
- Outlook: Management expects year-over-year improvement in operating income for the full year 2003 due to operating leverage from global infrastructure.
- New Product Launches:
- Infiniti Vision System: New tri-modal cataract removal system; first shipments expected in Q3 2003.
- AcrySof Natural IOL: FDA approved in June 2003; sales to commence in Q3 2003.
- Vigamox: FDA approved in April 2003; market entry in May 2003.
- Dividends: A dividend of $0.35 per share ($107.2 million total) was paid on June 4, 2003.
- Asset Sale: Entered an agreement to sell a contact lens manufacturing facility in Madrid, Spain, for approximately $22 million; closing projected for November 2003.
- Risks and Contingencies:
- Currency: Significant exposure to foreign exchange rates; a 10% depreciation in non-U.S. dollar currencies could decrease pre-tax earnings by approximately $29.0 million.
- Interest Rates: Majority of debt is short-term floating rate; a 1% increase in rates would decrease pre-tax earnings by $5.3 million.
- Regulatory/Litigation: Subject to product liability and patent litigation; outcomes are uncertain.
- Accounting Estimates: Significant judgments required for sales returns, inventory reserves, and goodwill impairment.
Investor Verification Checklist
- Constant Currency Growth: Verify the 10.1% (Q2) and 10.3% (6-month) organic sales growth rates to assess true operational performance independent of the weak U.S. dollar.
- Expense Leverage: Monitor SG&A and R&D expense ratios, which increased in 2003 due to new product launches; confirm if these normalize in subsequent quarters.
- Debt Structure: Review the high level of short-term borrowings ($1.43 billion) and the reliance on Nestlé guarantees for commercial paper facilities.
- Product Pipeline Execution: Track the commercial uptake of the Infiniti system, AcrySof Natural IOL, and Vigamox in Q3 and Q4 2003.
- Refractive Segment: Assess the continued decline in refractive sales due to global economic conditions and its impact on the surgical segment.